Products
The fixed combination Xultophy was approved in many countries and in the EU in 2014 as an injection solution in a prefilled pen. It was released in the United States in 2016.
Structure and properties
IDegLira is the name given to the combination of the insulin insulin degludec (IDeg, Tresiba) with the GLP-1 receptor agonist liraglutide (Lira, Victoza). Insulin is a derivative of human insulin, and liraglutide is an analog of the incretin GLP-1 (glucagon-like peptide-1).
Effects
IDegLira (ATC A10A) has blood glucose-lowering and antidiabetic properties. It lowers HbA1c levels. Insulin degludec is an ultra-long-acting basal insulin with a very long duration of action of more than 24 hours, a flat action profile, and stable pharmacokinetics. Among other benefits, liraglutide promotes insulin synthesis and release from beta cells, delays gastric emptying, and inhibits glucagon release.
Indications
For the treatment of type 2 diabetes mellitus. IDegLira is administered when blood glucose cannot be adequately controlled with metformin, metformin in combination with a sulfonylurea, or metformin in combination with a basal insulin.
Dosage
According to the SmPC. The drug is injected subcutaneously once daily always at the same time of day. Administration is possible regardless of meals.
Contraindications
IDegLira is contraindicated in cases of hypersensitivity. For complete precautions, see the drug label.
Interactions
There is a high potential for drug-drug interactions because numerous drugs affect blood glucose.
Adverse effects
The most common potential adverse effects include hypoglycemia and gastrointestinal symptoms: Nausea, diarrhea, vomiting, constipation, dyspepsia, gastritis, abdominal pain, poor appetite, flatulence, gastroesophageal reflux, and flatulence.